Booming atopic dermatitis market, Adtralza nears reimb
By Eo, Yun-Ho | translator Kim, Jung-Ju
24.02.15 17:32:14
가나다라
0
LEO Pharma has completed the drug pricing negotiations and is expecting an official launch
Adtralza offers a convenient dosing, allowing patients who achieve improved skin condition after initial treatment to consider dosing every fourth week
▲Adtralza (tralokinumab), a treatment for atopic dermatitis, is anticipated to be included in the reimbursement listing.
Adtralza, a treatment for atopic dermatitis, is expected to be the listed for insurance reimbursement.
According to the industry, LEO Pharma has completed the price negotiations with the National Health Insurance Service (NHIS) for Adtralza (tralokinumab), a treatment for atopic dermatitis with an underlying mechanism of neutralizing interleukin-13 (IL-13). Reimbursement for Adtralza will be available as soon as March, and the company is preparing for its official launch in May.
Adtralza was approved in Korea last August and passed the Cancer Drug Review Committee of the Health Insurance Review and Assessment Service (HIRA).
Adtralza is indicated for adults (18 ye
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)